Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371137 | 0.88 | GPR119 (0.60) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL1712980 | 0.87 | GPR119 (0.45) | GPR119KCNH2EGFRKCNE1 | |
| SCHEMBL1922732 | 0.87 | GPR119 (0.63) | GPR119KCNH2GPR183 | |
| SCHEMBL15109858 | 0.86 | GPR119 (0.52) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL2371631 | 0.86 | GPR119 (0.55) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL1713128 | 0.85 | GPR119 (0.43) | GPR119KCNH2EGFRKCNE1 | |
| SCHEMBL1842627 | 0.83 | GPR119 (0.55) | GPR119KCNH2GPR183 | |
| Oxalic Acid SCHEMBL15111770 | 0.83 | GPR119 (0.52) | GPR119KCNH2GPR183CYP3A4CYP2C19 | |
| SCHEMBL8071676 | 0.83 | GPR119 (0.55) | GPR119KCNH2GPR183 | |
| SCHEMBL2371746 | 0.82 | GPR119 (0.54) | GPR119KCNH2GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | claimed |
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| WO-2011113947-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | WO | claimed |
| US-20100048631-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | claimed |
| US-20130310398-A1 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| US-8513264-B2 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-20 | — | — | US | disclosed |
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20110263617-A1 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011113947-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | WO | disclosed |
| EP-2344195-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010029089-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-18 | — | — | WO | disclosed |
| US-20100048631-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048631-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048631-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| WO-2008081206-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310398-A1 | Combination therapy for the treatment of diabetes and related conditions | GPR119, DPP4, GLP1R | GPR119 1/4885KCNH2 3860/4885GPR183 183/4885 |
| US-20100048631-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | GPR119 1/4885KCNH2 1128/4885GPR183 45/4885 |
| US-20110263617-A1 | Combination therapy for the treatment of diabetes and related conditions | GPR119, DPP4, GLP1R | GPR119 1/4885KCNH2 3926/4885GPR183 155/4885 |
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | GPR119, DPP4, GLP1R | GPR119 1/4885KCNH2 3673/4885GPR183 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.